Japanese Nuclear Crisis Triggers Panic Buying Of Food And Drugs In China, Along With Selling Of Chinese Life Science Stocks
This article was originally published in PharmAsia News
Executive Summary
BEIJING - Virtual aftershocks from the 9.0 magnitude earthquake that rocked Japan, followed by a tsunami and a nuclear power plant crisis, are still reverberating across China
You may also be interested in...
Korea Begins To Assess Public Health, Industry Fallout From Japan Disaster
SEOUL - While a growing number of countries such as the U.S., Italy, France, Australia, New Zealand, Britain, China, India and Kyrgyzstan are urging their nationals in Japan to evacuate, South Korea on Thursday started checking radiation levels of people coming into the country from Japan
Southwest Japan-heavy Takeda And Dainippon Sumitomo Spared Earthquake Damage, Others May Rebound, But Tokyo Headquarters' Quieted By Rail Disruptions
TOKYO - Offices across Tokyo remained closed Tuesday, stalling the operations of headquarters for many pharma and medical device companies in Japan as the city faced train and highway closures and threats of blackouts through the rest of the week. Meanwhile, stocks for many of the Japanese pharma tumbled on the Nikkei March 14 in response to the emergency at power plants in Fukushima prefecture
Fresh Off BMS Deal, Leading Chinese CRO WuXi PharmaTech Outlines Plan To Expand Biologics Business To Keep Pace With Big Pharma
BEIJING - Betting on the belief that Big Pharma will speed up the transfer of research and manufacturing to China, leading contract research organization WuXi PharmaTech is expanding its chemistry services even while preparing to launch a new biologics testing and production center near its headquarters in Shanghai